A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection

Trial Profile

A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2016

At a glance

  • Drugs Surotomycin (Primary) ; Vancomycin
  • Indications Clostridium infections; Diarrhoea
  • Focus Therapeutic Use
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 17 Jul 2016 Results published in the Journal of Antimicrobial Chemotherapy (2016).
    • 20 Sep 2011 Results were reported at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 16 Jun 2011 Results have been reported in a Cubist Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top